Tonsillar tuberculosis in a rheumatoid arthritis patient receiving anti-TNFα (adalimumab) treatment

Netherlands Journal of Medicine

Volumn 63, Issue 3, 2005, Pages 112-114

  Efde, M N ^a   Houtman, P M ^a   Spoorenberg, J P L ^a   Jansen, T L Th A ^a  

^a MEDICAL CENTER LEEUWARDEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ANTIBIOTIC AGENT; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETHAMBUTOL; ISONIAZID; METHOTREXATE; PYRAZINAMIDE; RIFAMPICIN; SALAZOSULFAPYRIDINE; TUBERCULIN; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ADULT; ANOREXIA; ANTIBIOTIC SENSITIVITY; ARTICLE; CASE REPORT; CHEMOPROPHYLAXIS; CLINICAL FEATURE; COMBINATION CHEMOTHERAPY; COUGHING; DIAGNOSTIC PROCEDURE; DISEASE DURATION; DRUG INDICATION; DRUG USE; DRUG WITHDRAWAL; FEVER; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LUNG NODULE; MALE; MICROBIOLOGICAL EXAMINATION; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRESCRIPTION; RHEUMATOID ARTHRITIS; SCREENING TEST; SORE THROAT; THORAX RADIOGRAPHY; TONSILLITIS; TUBERCULIN TEST; TUBERCULOSIS;

ANTI-BACTERIAL AGENTS; ANTIBODIES, MONOCLONAL; ANTITUBERCULAR AGENTS; ARTHRITIS, RHEUMATOID; DIAGNOSIS, DIFFERENTIAL; DNA, BACTERIAL; DRUG THERAPY, COMBINATION; HUMANS; MALE; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; POLYMERASE CHAIN REACTION; RISK FACTORS; TONSIL; TUBERCULOSIS, LARYNGEAL; TUBERCULOSIS, PULMONARY; TUMOR NECROSIS FACTOR-ALPHA;

EID: 15544390809     PISSN: 03002977     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Olsen NJ, Stein CM. New drugs for rheumatoid arthritis. N Engl J Med 2004;350:2167-79.
2. Weinblatt ME, Keystone EC, Furst DE, et al. Adalimumab, a fully human anti-tumour necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate. Arthritis Rheum 2003;48:35-45.
3. Kroesen S, Widmer AF, Tyndall A, Hasler P. Serious bacterial infections in patients with rheumatoid arthritis under anti-TNF-α therapy. Rheumatology 2003;42:617-21.
4. Arend SM, Breedveld FC, van Dissel JT. TNF-α blockade and tuberculosis: better look before you leap. Neth J Med 2003;61:111-9.
5. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumour necrosis factor α-neutralising agent. N Engl J Med 2001;345:1098-104.
6. Gardam MA, Keystone EC, Menzies R, et al. Anti tumour necrosis factor agents and tuberculosis risk: mechanism of action and clinical management. Lancet Infect Dis 2003;3:148-55.
7. Prevoo ML, van Gestel AM, van't Hof HA, van Rijswijk MH, van de Putte LB, van Riel PL. Remission in a prospective study of patients with rheumatoid arthritis. American Rheumatism Association preliminary remission criteria in relation to the disease activity score. Br J Rheum 1996;35:1101-5.
8. Kox LF, Noordhoek GT, Kunakom M, Mulder S, Sterrenburg M, Kolk AH. Microwell hybridization assay for detection of PCR products from Mycobacterium tuberculosis complex and recombinant smegmatis strain 1008 used as an internal control. J Clin Microbiol 1996;34:2117-20.
9. Keystone E, Haraoui B. Adalimumab therapy in rheumatoid arthritis. Rheum Dis Clin N Am 2004;30:349-64.
10. Selimoglu E, Sutbeyaz Y, Ciftcioglu A, et al. Primary tonsillar tuberculosis: a case report. J Laryngol Otol 1995;109:880-2.
11. Hajioff D, Snow MH, Thaker H, Wilson JA. Primary tuberculosis of the posterior oropharyngeal wall. J Laryngol Otol 1999;113:1029-30.
12. Derk CT, Dehoratius RJ. Tuberculous tonsillitis in a patient receiving etanercept treatment. Ann Rheum Dis 2003;62:372.
13. Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med 2000;161(suppl):S221-47.
14. Kim HA, Yoo CD, Baek HJ, et al. Mycobacterium tuberculosis infection in a corticosteroid-treated rheumatic disease patient population. Clin Exp Rheumatol 1998;16:9-13.
15. Breedveld FC, van Albada-Kuipers GA, van den Hoogen FHJ. Richtlijn: het toepassen van TNF-blokkade in de behandeling van reumatoïde artritis. Ned Tijdschr Reumatol 2004;1:11-2.
16. International Union Against Tuberculosis Committee on prophylaxis. Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years follow-up in the IUAT-trial. Bull World Health Organ 1982;4:555-64.
17. Official ATS CDC Update: fatal and severe liver injuries associated with rifampicin and pyrazinamide for latent tuberculosis infection, and revisions in American Thoracic Society/CDC recommendations - United States, 2001. Am J Resp Crit Care Med 2001;164:1319-20.